Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC

Lancet Respir Med. 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3.

Authors

Se-Hoon Lee¹, June-Koo Lee²

Affiliations

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea. Electronic address: shlee119@skku.edu.
² Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.

PMID: 28145234
DOI: 10.1016/S2213-2600(17)30010-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms
Proto-Oncogene Proteins c-ret
Quinazolines*

Substances

Antineoplastic Agents
Quinazolines
Proto-Oncogene Proteins c-ret
RET protein, human